IRAK4-IN-6 是一种口服高效、选择性 IRAK 抑制剂，IC50 为 4 nM，靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。
| Cas No. | 2454244-02-9 |
| Canonical SMILES | O=C(N1CCN([C@@H]2CC[C@@H](NC3=C4C(C=CC(CC#N)=N4)=NC(NC5=CN(C)N=C5)=N3)CC2)CC1)OC |
| 分子式 | C25H32N10O2 |
| 分子量 | 504.59 |
| 溶解度 | DMSO : 125 mg/mL (247.73 mM) |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma[1]. References:
[1]. Degorce SL, et al. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors TargetingMyD88L265P Mutant Diffuse Large B Cell Lymphoma. J Med Chem. 2019 Nov 1. |
